1. The validation mostly measures recovery of the same contact rules used for supervision
Phase-II positives and negatives are defined by contact and interaction-type agreement (Appendix A.1.1). The representation is then evaluated against residue overlap and IFA, which are built from the same general contact information. The high correlations in Appendix C.1 therefore establish consistency among related geometric descriptors; they do not independently establish preservation of binding determinants or PPI inhibition.
This distinction matters for the central claim. Two molecules can make similar contacts while differing greatly in affinity because of desolvation, strain, conformational entropy, or the energetic importance of particular residues. Conversely, a useful small molecule may reproduce a small subset of peptide hotspots rather than a large fraction of its contacts.
Please add a direct, nonlearned pharmacophore/contact-matching guidance baseline under the same adapted prior and sampling budget. This would test whether the learned embedding contributes beyond its input representation. An independent evaluation using known active/inactive compounds, experimentally characterized hotspots, or held-out pose discrimination would make the biological interpretation substantially stronger. Experimental assays would be valuable, but my concern is the lack of independent validation, not a blanket requirement for wet-lab work.
The IFA definition itself needs clarification. It sums residue-wise cosine similarities over the union of contacted residues, including cases where one vector is zero; cosine is undefined there unless a convention is specified. With the natural zero-contribution convention, additional contacts to residues absent from the reference are not penalized. Moreover, when both vectors contain only the same single interaction type, their cosine is one regardless of the distance weights. Thus, IFA is neither a normalized interface similarity nor generally a measure of distance agreement. Reporting precision is helpful, but the paper should explicitly characterize these limitations, compare normalized alternatives, and test sensitivity to contact thresholds. A common IFA threshold of 1.5 can also represent different levels of recovery for peptides with different interface sizes.
2. The central differentiable interface construction is not sufficiently specified
Equations (12)–(13) write the pharmacophore cloud formula, but the manuscript does not define how Φ supports gradients through changes in building-block identity. Straight-through Gumbel–Softmax supplies a surrogate derivative for a categorical choice; it does not automatically make reaction assembly, atom indexing, pharmacophore typing, or ProLIF contact detection differentiable.
Different building blocks can contain different numbers of atoms and different reactive centers. Please specify how their atoms and coordinates share a tensor representation, how reaction validity and feature masks are handled, and what continuous relaxation carries gradients from interface features back to logits. For coordinate guidance, explain whether contacts and feature identities are frozen during each update or recomputed through a smooth surrogate. Hard contact thresholds can yield a piecewise-defined objective, which is not necessarily unusable, but its behavior needs to be described.
The geometric features ρi and ρij also need explicit formulas. For fixed point types and masks, separate encoders using only within-cloud invariant geometry would be insensitive to rigidly moving the binder relative to the target. The target-dependent contact extraction can already encode some relative information by changing which features are present, so the complete pipeline need not have this limitation. Please explain whether pose sensitivity comes from that extraction, explicit cross-cloud geometric features, or both, and how it supplies coordinate gradients. A displaced/rotated-binder control with contacts recomputed would be informative. This is a request to clarify the pipeline, not a claim that it ignores the target.
These details are central to the claimed contribution. A precise algorithm, tensor dimensions, and a small gradient sanity check would be more helpful than additional high-level diagrams.
3. Most of the docking improvement cannot currently be attributed to peptide guidance
PIFT uses a target-specific prior optimized with a reward containing Vina and QEPPI, while the headline comparison is largely against generators without the same adaptation. This is a reasonable system comparison, but it does not isolate the contribution of the peptide representation or joint guidance. Optimizing the reported docking function is also a different setting from generalizing to an independent binding evaluator.
The controlled Off comparison is therefore especially important. Figure 4b reports:
| Metric | Off | Joint guidance | Change |
|---|
| IFA | 1.975 | 2.049 | +0.074, approximately 3.75% |
| Contact precision | 0.448 | 0.460 | +0.012 |
| Vina | −7.662 | −7.703 | −0.041 kcal/mol |
| Joint success | 25.3% | 29.3% | +4.0 percentage points |
These are potentially useful improvements, but much smaller than the full-system comparison with SynCoGen. Coordinate-only guidance also gives a slightly better docking mean than joint guidance. The results suggest a modest multi-objective benefit; they do not yet justify attributing the broad docking advantage to peptide transfer.
Please report the full target-level matrix for the original backbone, adapted Off prior, direct-contact guidance, learned guidance, and each guidance branch. Include paired differences and confidence intervals across targets and independent runs. Appendix C.4 already provides a useful size-regression control, but this controls molecular size, not adaptation budget, reward optimization, or the value of the learned representation.
The MDM2 reference-switch experiment is a good control, although the displayed self/cross IFA gains are small: approximately 0.019/0.005 and 0.021/0.009 in Figure 6a. Without uncertainty and additional targets, “clear reference-dependent guidance” is stronger than the evidence currently warrants.
4. The amount of effective cross-modal supervision and its generalization need closer examination
The initial corpus is substantial, but Appendix A.1.1 reports only 82 eligible peptide queries across 18 targets for target-conditioned alignment. This is the relevant supervision scale for the central cross-modal stage, and it should be visible in the main text.
Please report the number of held-out queries, targets, and pairs, the contribution of each structural source, and the exact relationship between the ten generation targets and every training stage. Accession-disjoint encoder splits do not automatically establish that the evaluation targets are unseen by the generative backbone. Conversely, target-specific reward adaptation is intentional and should be described as adaptation, rather than conflated with zero-shot generalization.
The Phase-II labels are also coarse: a positive needs nonzero agreement, whereas a negative has zero agreement and a nearby pocket centroid. This can teach the encoder to distinguish some overlap from none without learning how to prioritize energetically important interactions. More challenging negatives with similar contact counts, matched molecular size, and perturbed poses would test the intended capability.
Table 7 gives a pair-ranking accuracy of 0.598 ± 0.042, compared with 0.572 ± 0.029 without target conditioning. This is encouraging but modest. Please define what the uncertainties represent and report a paired comparison. The strong pooled trends in Figure 3 should not replace this harder query-level generalization result.
5. Evaluation budgets, failures, and molecular trade-offs need a more complete account
Table 6 specifies 256 samples per target and five docking seeds, whereas Figure 4c extends beyond 50,000 sampling steps/candidates on its budget axis. Please explain whether that figure pools targets, uses a separate large experiment, counts proposals or accepted molecules, and includes the samples used for prior adaptation. The “approximate 95% interval” needs a defined resampling unit and construction. Because discovery modes are accepted sequentially by Tanimoto distance, ordering can change the count; random-order repetitions or a fixed clustering procedure would help.
The baseline failures also need a concrete diagnosis. Peptide2Mol has validity 0.088 and several missing targets, while FLOWR has a degenerate BCL2 result. Such results may be real, but the general explanation that diffusion and flow matching require a localized cavity is too broad—PIFT itself uses both mechanisms, and the paper describes baselines that can accept peptide or interaction information. Report versions, conditioning setup, docking boxes, validity filters, and failure counts, with suitable positive controls for the baseline implementations.
Missing-target handling changes the interpretation of averages. For example, TargetDiff's −6.27 average is consistent with averaging its eight successful targets, while PIFT's −7.68 uses all ten. Report conditional docking means alongside unconditional valid/docked yield and common-target comparisons. Restricting PoseCheck to complete methods is transparent, but the other aggregate metrics need equally explicit denominators.
Finally, Table 3 shows a meaningful trade-off: PIFT's diversity is 0.709, the lowest reported, compared with 0.804 for SynCoGen. Its AiZynthFinder success rate is 0.612 versus 0.643, and validity is 0.947 versus 0.957. These do not negate the docking gains, but they qualify the claim of broadly favorable molecular properties. PoseCheck interaction counts alone do not establish pose plausibility; report clashes and strain as well. Successful route prediction or construction from reaction templates should be described as predicted synthetic feasibility.
We sincerely thank the reviewer for their time and careful assessment of our results. Although some experiments are still ongoing, we are continuing this work based on the reviewer’s suggestions for further evaluation. Below, we report additional analyses addressing the limitations of IFA.
W1. Clarifying and Complementing IFA
We agree that the current IFA definition has limitations. Although residue-wise cosine similarity captures differences in interaction-type profiles, it is insensitive to distance weights when both profiles contain only the same single interaction type. With zero-vector contributions defined as zero, contacts to residues absent from the peptide reference do not reduce the summed IFA.
To address the latter limitation, we additionally report normalized IFA and interaction-pair precision. Normalized IFA divides the summed score by the number of residues contacted by either binder. Interaction-pair precision measures the fraction of ligand (residue, interaction-type) pairs also present in the peptide reference. We include recall and F1 to characterize the balance between interaction recovery and additional contacts.
Our method has the highest normalized IFA, recall, and F1, though the gains over guidance-off sampling are small. Its precision is lower than that of several baselines, suggesting that it recovers more reference interactions but also makes additional contacts. The added metrics account for these contacts, while IFA’s limited sensitivity to distance differences remains.
We are also considering how to distinguish additional target interactions arising from small-molecule chemistry that may support binding from those that are unnecessary, and how to assess their compatibility with the peptide reference. Developing a concrete metric that captures this distinction remains an important direction for our work. We thank the reviewer for raising this question and helping us identify this direction for improvement.